Resources Repository
-
ReportPublication 2017DCP3: Improving Health and Reducing Poverty
This report from the World Bank is the ninth and final volume of the Disease …
This report from the World Bank is the ninth and final volume of the Disease Control Priorities, Third Edition (DCP3) series. It provides an overview of the findings and methods explored in the first eight volumes, placing them within a framework that identifies an efficient pathway toward essential universal health coverage through the implementation of 21 essential packages that include health interventions and fiscal and intersectoral policies. The Disease Control Priorities Network (DCP) promotes and…
Cost-Effectiveness Analysis | Mental Health | Benefit-Cost Analysis | Costing Methods | Health Outcomes | Evidence Synthesis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Social Determinants | Health Systems | Policy/Regulation | Global Governance | Economics/Finance | Government/Law | Health/Medicine | Science/Technology | Global -
Resource PackWeb Portal, Teaching Resource 2018Resource Pack: Mental Health and Modeling
This resource pack, curated by the Center for Health Decision Science, features resources on modeling …
This resource pack, curated by the Center for Health Decision Science, features resources on modeling approaches applied to mental health. We aim to provide an overview of different techniques to guide researchers and practitioners in applying decision science and economic modeling to this public health challenge. More specifically, this resource pack contains review articles comparing different modeling techniques in the evaluation of treatments for depression, bipolar disorder and schizophrenia. The majority of articles in this…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Costing Methods | Health Outcomes | Evidence Synthesis | Mathematical Models | Microsimulation | Chronic Disease/Risk | Health/Medicine | North America | Europe -
ReviewPublication 2017Model-Based Economic Evaluation of Treatments for Depression: A Systematic Review
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies …
This article, published in Pharmacoeconomics, systematically reviews the literature in order to identify model-based studies evaluating the cost-effectiveness of treatments for depression and examine the appropriateness of different modelling technique for simulating the natural course of depression. The review yielded 41 model-based studies, of which 21 used decision trees (DTs), 15 used cohort-based state-transition Markov models (CMMs), two used individual-based state-transition models (ISMs), and three used discrete-event simulation (DES) models. Just over half of the…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Mathematical Models | Microsimulation | Health/Medicine -
ReportPublication 2017Economic Value of Informal Mental Health Caring
Caregivers, family and friends play a significant role in supporting people with mental illness, and …
Caregivers, family and friends play a significant role in supporting people with mental illness, and it has long been recognized that informal carers constitute a significant ‘hidden’ workforce in Australia. Faced as Australia is with an ageing population and burgeoning chronic disease, data on the contribution that carers make and the consequent savings to governments and other ‘payers’ need to be articulated. This report attempts to put a ‘value’ on informal caring for those with mental illness.…
Cost-Effectiveness Analysis | Mental Health | Benefit-Cost Analysis | Preferences/Values | Costing Methods | Health Outcomes | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Oceania -
Resource PackPublication, Teaching Resource 2017Resource Pack: Disease Control Priorities
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced …
This resource pack, curated by the Center of Health Decision Science, showcases selected analyses produced by the Disease Control Priorities 3 (DCP3) to inform program design and resource allocation at the global and country levels. Analyses focus on the effectiveness, cost, and cost-effectiveness of priority interventions. Learn more by visiting the DCP3 website.
Cost-Effectiveness Analysis | Mental Health | Benefit-Cost Analysis | Costing Methods | Evidence Synthesis | Infectious Diseases | Maternal/Reproductive Health | Child/Nutrition | Chronic Disease/Risk | Injuries/Accidents | Health Systems | Economics/Finance | Health/Medicine | Global | College | Graduate | Doctoral | Professional | Critical Thinking/Analysis | Policy Translation | Quantitative Literacy -
ArticlePublication 2016Cost-Effectiveness of Collaborative Care for Depression and Comorbid Diabetes or CVD
This article, published in BMJ Open, presents an economic model that combines a decision tree …
This article, published in BMJ Open, presents an economic model that combines a decision tree and a Markov cohort model to investigate the long-term cost-effectiveness of collaborative care versus usual care for individuals with depression and comorbid diabetes and/or cardiovascular disease. Data from the COINCIDE trial informs the model input parameters. The COINCIDE trial is a randomized controlled trial of collaborative care versus usual care that enrolled 387 participants from 36 primary care general practices…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Chronic Disease/Risk | Health/Medicine | Europe -
ArticlePublication 2016Challenges of Prioritization
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and …
Cost-effectiveness analysis has traditionally been applied primarily to very specific interventions, such as drugs and diagnostics; in addition, the evidence base drawn on for evaluating such interventions is relatively good, given the medical research industry surrounding their testing. However, with increasing success in controlling infectious diseases, many of the health challenges facing countries concern broad threats to health with multiple causes, such as obesity, where the relationship between policy action and health benefit is not…
Cost-Effectiveness Analysis | Mental Health | Benefit-Cost Analysis | Priority Setting/Ethics | Infectious Diseases | Chronic Disease/Risk | Health Systems | Economics/Finance | Health/Medicine | Global -
ReportPublication 2015Modeling to Improve Policy Decisions in the Americas: Noncommunicable Diseases
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only …
In the Region of the Americas, noncommunicable diseases (NCDs) are a clear threat not only to human health, but also to a country’s economic development and growth. The evidence on both of these counts is compelling. In 2012, cardiovascular disease, diabetes, cancers, chronic respiratory conditions including asthma, and other NCDs were the cause of 4.5 million deaths in the Americas. Of that total number, 1.5 million of them were premature, occurring among people aged 30-69…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Priority Setting/Ethics | Costing Methods | Mathematical Models | Microsimulation | Decision Analysis | Chronic Disease/Risk | Health/Medicine | Latin America & Caribbean -
ArticlePublication 2014Cost-Effectiveness of Second-Generation Antipsychotics for the Treatment of Schizophrenia
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness …
This article, published in Value in Health, describes a Markov model that compares the cost-effectiveness of alternate sequences of treatment strategies using second-generation antipsychotics (SGAs) for patients with schizophrenia. First-line treatments include one of the four SGAs: olanzapine (OLZ), risperidone (RSP), quetiapine (QTP), and ziprasidone (ZSD). Patients are able switch to another of these antipsychotics as second-line therapy, and only clozapine (CLZ) is allowed as third-line treatment. Model input parameters were obtained from the Clinical…
Cost-Effectiveness Analysis | Mental Health | State-Transition | Health/Medicine | North America